JFJuan Pablo Fraga

Juan Pablo Fraga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Pablo Fraga has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PROTEGO Study Protocol: A Cluster Randomised Crossover Trial of Vernix Caseosa Retention for Primary Prevention of Atopic Dermatitis

    by Arturo Borzutzky, Carolina Cabalín, Juan Pablo Fraga, Jorge Fabres, Alberto Toso, Marcelo Farías, María Laura Cossio, María José Escalante, Paula Fajuri, Maite Rojas‐Mckenzie, et al.

    Summary: PROTEGO is a Chilean cluster‐randomised crossover trial of vernix caseosa retention to prevent atopic dermatitis. 1383 mother‐infant dyads will be enrolled and followed for atopic dermatitis until 12 months.

  • Open Access

    Association of Vitamin D Status With Total and Site‐Specific Cancer Mortality From Tropical to Subantarctic Latitudes: A Nationwide Population‐Based Study in Chile

    by Gonzalo Muñoz, Juan Pablo Fraga, Ignacia S. Núñez‐Ulloa, Alvaro Passi‐Solar, Bruno Nervi, Sebastián Mondaca, Paula Margozzini, Carlos A. Camargo, Arturo Borzutzky

    Background: An association of low vitamin D (VD) status with increased cancer mortality has been described, and Chile provides an ideal setting to evaluate this association given its extensive latitude span (17°S–56°S). Methods: We performed a nationwide population‐based ecological study of all and specific cancer deaths from 2002 to 2020, in which mean 25(OH)D concentrations were obtained from the 2017 Chilean National Health Survey and associations with cancer deaths were assessed across 48 provinces. Multiple regression models including body mass index and tobacco use were performed to account for other carcinogenic factors. Results: For the studied period, 446,237 cancer‐associated deaths were reported. Provincial mean 25(OH)D ranged between 11.8 and 25.8 ng/mL, displaying a significant north–south decreasing gradient, and provincial mean 25(OH)D concentrations were inversely correlated with age‐standardized death rates for multiple cancer types, being strongest for breast, kidney, and liver cancer. Multiple regression models revealed significant inverse associations for 21 of the 27 cancer types analyzed, being strongest for endometrial, thyroid, colorectal, liver, kidney, and larynx cancer. Conclusions: Significant inverse associations between 25(OH)D concentrations and multiple cancer‐type mortality were found across Chile, confirming the association of low VD status with colorectal and breast cancer mortality, while providing novel ecological evidence of an inverse association between 25(OH)D concentrations and several cancer types for which a relationship with VD has been less established. These findings should inform public policies regarding cancer screening and treatment across different latitudes, and prompt evaluation of VD supplementation and fortification for reduction of site‐specific cancer mortality.


  • Determinants and clinical associations of total, bioavailable, and free 25-hydroxyvitamin D in children with atopic dermatitis

    by Juan Pablo Fraga, María Francisca Bustos, Carolina Iturriaga, Guillermo Pérez‑Mateluna, Carolina Cabalín, Carla Leiva, Carlos A. Camargo, Arturo Borzutzky

  • Early Use of Proton Pump Inhibitors Increases Risk of Upper Respiratory Tract Infections in Children: A Birth Cohort Study

    by Maite Rojas‐McKenzie, Juan P. Fraga, Carolina Iturriaga, Caroll Hernández, Guillermo Pérez‐Mateluna, Marcela Urzúa, Carolina A. Serrano, Paola Casanello, Paul R. Harris, José A. Castro‐Rodríguez, et al.

    Objectives: Proton pump inhibitors (PPI) are frequently prescribed in infancy for functional gastrointestinal disorders such as colic and gastroesophageal reflux, despite limited evidence of benefit and potential risk. We aimed to examine the association between early PPI exposure and respiratory tract infections (RTIs) in a birth cohort. Methods: In the ARIES cohort (Santiago, Chile), 200 of 265 children with complete data were followed from birth to 24 months. Early PPI exposure was defined as any use during the first 6 months, while any exposure encompassed the first 24 months. Clinical data were collected via parental questionnaires and medical records. Associations were assessed using logistic regressions. Results: Sixteen infants (8%) received PPIs during the first 6 months and 22 (11%) during the first 2 years. By age two, otitis media occurred in 12%, viral croup in 18%, bronchiolitis in 36%, pneumonia in 2.5%, RTI‐related hospitalization in 3%, and RTI‐related antibiotic use in 38%. Early PPI exposure was independently associated with otitis media (adjusted odds ratio [aOR] 9.5, 95% CI 2.1−42.5), viral croup (aOR 4.8, 95% CI 1.5−15.2), RTI‐related hospitalization (aOR 19.3, 95% CI 1.6−225.8), and antibiotic use (aOR 9.9, 95% CI 2.5−38.6). Any PPI exposure also increased odds of otitis media (aOR 5.4, 95% CI 1.4−21.0), viral croup (aOR 3.0, 95% CI 1.1−8.1), RTI‐related hospitalization (aOR 17.5, 95% CI 1.5−205.0), and antibiotic use (aOR 8.9, 95% CI 2.9−27.1). No significant associations were observed with lower RTIs. Conclusions: Early PPI exposure in infancy is associated with higher risk of upper RTIs, RTI‐related hospitalization and antibiotic prescriptions. These findings underscore the importance of cautious PPI prescribing in early life, a critical period for immune and microbiota development.

  • Open Access

    Safety, tolerability, bioavailability, and biological activity of inhaled interferon-α2b in healthy adults: The IN2COVID phase 1 randomized trial

    by Diego Garcia-Huidobro, Carolina Iturriaga, Guillermo Perez-Mateluna, Paula Fajuri, Nicolas Severino, Marcela Urzua, Juan Pablo Fraga, Javiera de la Cruz, Cecilia Poli, Jose Castro-Rodriguez, et al.

    Aim: Interferons (IFNs) have been identified as a potential treatment alternative for Coronavirus Disease 19 (COVID-19). This study assessed the safety, tolerability, bioavailability, and biological activity of inhaled interferon-α2b (IFN-α2b) in healthy adults. Methods: A double-blind, randomized, phase 1 clinical trial was conducted with two cohorts of healthy subjects aged 18-50 years old. The first cohort received 2.5 MIU of inhaled IFN-α2b twice daily for 10 days (n=6) or placebo (n=3); the second cohort received 5.0 MIU of inhaled IFN-α2b in a similar scheme (n=6) or placebo (n=3). The first two doses were administered in an Emergency Department, then participants completed their treatment at home. Safety was measured through vital signs, new symptoms, and laboratory tests. Tolerability was measured as the participant´s treatment acceptability. Bioavailability and biological activity were measured from serum IFNα levels and real-time quantitative PCR of interferon-induced genes in blood before and after treatments. Results: Exposure to inhaled IFN-α2b at 2.5 MIU or 5 MIU doses did not produce significant changes in participant vital signs, or elicit new symptoms, and standard hematological and biochemical blood measurements were comparable to those recorded in individuals who received placebo. All adverse events were mild or moderate and did not require medical care. Participants reported very high tolerability. A dose-dependent mild increase in serum IFN-α concentrations and an increase in serum RNA expression of IFN-induced genes were observed after treatment. Conclusion: Inhaled IFN-α2b was safe, well-tolerated, and induced systemic biological activity in healthy subjects.